Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juni 2023

Genmab — Juni 2023

Planlagt Fastgjort Låst Flyttet Genmab
702 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • StockBullS Offline
    StockBullS Offline
    StockBull
    wrote on sidst redigeret af
    #126

    Ja sidste år rykkede den fra 1862 til 3212. I år har vi en højere bund forhåbentlig også en højere top inden udgang af 2023.

    1 Reply Last reply
    0
    • StockBullS Offline
      StockBullS Offline
      StockBull
      wrote on sidst redigeret af
      #127

      Med udsigt til lavere renter i 2024 burde det snart blive medtaget i diverse analytiker targets lige så snart FED informere renten har toppet. PE værdien ligger normalt en del højere når renten er lav under 2%

      1 Reply Last reply
      0
      • P Offline
        P Offline
        ProinvestorNEWS
        wrote on sidst redigeret af
        #128

        Kort video: Gevinsthjemtagning i Novo, Zealand Pharma og Genmab : https://www.proinvestor.com/boards/113030

        1 Reply Last reply
        0
        • K Offline
          K Offline
          Klarussen
          wrote on sidst redigeret af
          #129

          Gode kommentarer, tak for det Helge 😉

          1 Reply Last reply
          0
          • Legolas23L Offline
            Legolas23L Offline
            Legolas23
            wrote on sidst redigeret af
            #130

            ?

            1 Reply Last reply
            0
            • Legolas23L Offline
              Legolas23L Offline
              Legolas23
              wrote on sidst redigeret af
              #131

              Hva skete der lige?

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #132

                Us åbnede. Det er sket tit.

                1 Reply Last reply
                0
                • BulderB Offline
                  BulderB Offline
                  Bulder
                  wrote on sidst redigeret af
                  #133

                  Nu må vi se om det holder. Omsætning meget lav.

                  1 Reply Last reply
                  0
                  • BulderB Offline
                    BulderB Offline
                    Bulder
                    wrote on sidst redigeret af
                    #134

                    Lige nu står det stille - igen.

                    1 Reply Last reply
                    0
                    • K Offline
                      K Offline
                      Klarussen
                      wrote on sidst redigeret af
                      #135

                      Lidt mærkværdigt, men man kan håbe på en sektorrotation in i healthcare og andre defensive sektorer igen, der er vist ikke på kort sigt meget krudt tilbage i AI/tech

                      1 Reply Last reply
                      0
                      • BulderB Offline
                        BulderB Offline
                        Bulder
                        wrote on sidst redigeret af
                        #136

                        Omsætningen er fordoblet i den halve time us har været åben. Fra 5000 stk til 11000 stk! Rekordlavt

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #137

                          Kursgrafen ser sjov ud. Op og ned.

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            gdn55
                            wrote on sidst redigeret af
                            #138

                            Trods alt lidt omsætning i lukkeaktionen, godt dobbelt op på de fem minutter.

                            1 Reply Last reply
                            0
                            • B Offline
                              B Offline
                              bikube
                              wrote on sidst redigeret af
                              #139

                              Knap 16 K Warrants og RSU. det har vi set værre.

                              1 Reply Last reply
                              0
                              • Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktør
                                wrote on sidst redigeret af
                                #140

                                Grant of Restricted Stock Units and Warrants to Employees in Genmab https://www.proinvestor.com/investornyt/998687/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab

                                1 Reply Last reply
                                0
                                • P Offline
                                  P Offline
                                  ProinvestorNEWS
                                  wrote on sidst redigeret af
                                  #141

                                  Aktier: 4 grunde til at investorerne har taget tyren ved hornene. Danske aktier i overhalingsbanen med fed energi fra Novo Nordisk https://www.proinvestor.com/boards/113062

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #142

                                    Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023 https://ir.genmab.com/news-releases/news-release-details/genmab-showcases-data-comprehensive-epcoritamab-development

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #143

                                      Both Talquetamab and Epcoritamab on the COMP agenda for next week under '4. Review of orphan designation for orphan medicinal products
                                      at time of initial marketing authorisation' https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-13-15-june-2023_en.pdf

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #144

                                        results from 2 cohorts in EPCORE NH2 investigating epcoritamab+rituximab & lenalidomide in patients with R/R FL. This combination showed potent anti-tumor activity and a manageable safety profile in patients with high-risk disease #lymsm https://twitter.com/lymphomahub/status/1667162491560837120

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #145

                                          @NBahlis
                                          presents results of the TRIMM-2 trial (talquetamab + daratumumab), targeting GPRC5D & CD38, ORR of 84% w/ response rate within 1st round of therapy.
                                          **Impressively, 78.6% pts were refractory & heavily pre-exposed to a CD38 https://twitter.com/MyelomaCanada/status/1667475172201201664 https://twitter.com/MM_Hub/status/1667475083022024707

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper